PMA most commonly stands for Premarket Approval, the FDA’s rigorous review process for high-risk medical devices. It can also refer to Progressive Muscular Atrophy, a rare motor neuron disease. Because these are entirely different topics, this article covers both meanings so you can jump to the one you’re looking for.
PMA as FDA Premarket Approval
Premarket Approval is the process the FDA uses to evaluate whether Class III medical devices are safe and effective before they can be sold in the United States. Class III devices are the highest-risk category: things like pacemakers, implantable defibrillators, and replacement heart valves. These are devices that sustain human life, prevent serious health problems, or carry a significant risk of illness or injury.
Because the stakes are so high, the FDA requires manufacturers to submit extensive scientific evidence proving their device works and won’t harm patients. This makes PMA the most stringent type of device review the agency conducts, comparable in scope to the process a new drug goes through before reaching the market.
How PMA Differs From 510(k) Clearance
If you’ve seen medical devices described as “FDA cleared” rather than “FDA approved,” that’s a different, lighter-touch pathway called a 510(k). Lower-risk devices (Class I and Class II) can reach the market by showing they’re substantially equivalent to a device already being sold, matching it in intended use, design, and other key features. No original clinical trials are necessarily required.
PMA is fundamentally different. There’s no shortcut of pointing to an existing product. The manufacturer must generate its own body of evidence, typically including human clinical trials, to independently prove safety and effectiveness. The distinction matters for patients: a device that went through PMA has been scrutinized at a much deeper level than one that was 510(k) cleared.
What a PMA Application Contains
A PMA submission is a large, detailed package. It includes preclinical laboratory studies (bench testing, animal studies), manufacturing details showing the device can be produced consistently, and, most importantly, clinical data from human trials. The FDA’s standard is “valid scientific evidence,” which can come from well-controlled investigations, partially controlled studies, objective trials, or well-documented case histories. In practice, the agency expects the core evidence to come from well-controlled clinical investigations with human subjects.
Manufacturers also submit proposed labeling, descriptions of the device’s components and how it works, and a summary of any risks identified during testing. The goal is to give the FDA enough information to conclude there is “reasonable assurance” the device is both safe and effective for its intended use.
Review Timeline and Cost
The FDA’s current performance goal for original PMA applications is a decision within 180 FDA review days for 90% of submissions. When an advisory committee of outside experts needs to weigh in, that window extends to 320 days. Factoring in time the manufacturer spends responding to FDA questions, the combined target for total time to decision is 285 calendar days.
PMA applications carry a user fee that manufacturers must pay when they submit. Small businesses, defined as companies with $100 million or less in annual gross receipts, pay 50% of the standard fee. The exact dollar amounts are updated each fiscal year and published in the Federal Register.
What Happens After Approval
Getting a PMA approval isn’t the finish line. The FDA can impose postapproval requirements, including ongoing studies to monitor the device’s long-term safety and reliability. Manufacturers must file annual reports that detail any changes made to the device and summarize new clinical or nonclinical data collected over the previous year.
Manufacturers are also required to report any deaths or serious injuries their device may have caused or contributed to. They must maintain files on adverse events and can be ordered to conduct formal postmarket surveillance studies if the FDA determines that a device failure could have serious health consequences. Continued approval hinges on meeting these obligations.
PMA as Progressive Muscular Atrophy
In neurology, PMA stands for Progressive Muscular Atrophy, a rare motor neuron disease that strikes adults. It belongs to the same family of conditions as ALS (amyotrophic lateral sclerosis) but has a distinct pattern. Where ALS affects both upper and lower motor neurons, PMA primarily damages the lower motor neurons, the nerve cells that directly control muscle movement.
The disease typically starts in the hands, which accounts for nearly half of all cases. Less commonly, it begins in the lower limbs, shoulder area, or muscles involved in speech and swallowing. Early signs include muscle wasting and weakness in one area that gradually spreads to neighboring regions. Fasciculations, the small involuntary muscle twitches visible under the skin, are a hallmark finding. Cramps are common, and reflexes in weakened limbs tend to be reduced or absent. Importantly, there are no sensory symptoms: numbness, tingling, and pain are not part of the picture.
About 15% of people diagnosed with a sporadic motor neuron disease present with this pure lower motor neuron pattern. Over time, however, the boundaries between PMA and ALS can blur. Roughly 20% to 30% of people initially diagnosed with PMA develop upper motor neuron signs within 5 to 10 years, and some research suggests that figure may climb as high as 70% over a longer follow-up. This overlap is why neurologists consider PMA a variant of ALS rather than a completely separate disease, though its rate of progression and prognosis can differ.